何宇 1,2 , 羅靜 1 , 周蕾蕾 1
  • 1.四川省醫(yī)學(xué)科學(xué)院·四川省人民醫(yī)院乳腺外科（四川成都 610072）;;
  • 2.瀘州市人民醫(yī)院外二科（四川瀘州 646100）;

目的 　探討雄激素受體（AR）和Stathmin在三陰性乳腺癌患者中的表達情況并分析此與臨床病理因素的相關(guān)性。
方法 　回顧性收集2005～2009年期間在四川省人民醫(yī)院乳腺外科確診為三陰性乳腺癌并符合納入條件患者共83例。使用免疫組織化學(xué)EnVision二步法檢測AR和Stathmin蛋白在三陰性乳腺癌中的表達情況。用Spearman檢驗分析AR和Stathmin表達與患者年齡、腫瘤大小、淋巴結(jié)狀態(tài)及病理分級的相關(guān)性。
結(jié)果 　AR和Stathmin在三陰性乳腺癌組織中表達陽性率分別為37.3% （31/83）和98.8% （82/83）。AR的表達與年齡呈正相關(guān)
（rs=0.302，P=0.006），與腫瘤病理分級也呈正相關(guān)（rs=0.225，P=0.041），而與腫瘤大小和淋巴結(jié)狀態(tài)無關(guān)（P＞0.05）。
Stathmin的表達與患者年齡、腫瘤大小、淋巴結(jié)狀態(tài)及病理分級均無關(guān)（P＞0.05）。
結(jié)論 　AR表達與乳腺癌患者的年齡及腫瘤分級有關(guān)，而Stathmin與生物學(xué)行為無關(guān)，其作為三陰性乳腺癌預(yù)后判斷指標(biāo)還需要進一步研究。

引用本文： 何宇,羅靜,周蕾蕾. 雄激素受體、Stathmin與三陰性乳腺癌臨床病理因素相關(guān)性的初步探討. 中國普外基礎(chǔ)與臨床雜志, 2013, 20(8): 846-850. doi: 復(fù)制

1. Gluz O， Liedtke C， Gottschalk N， et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol， 2009， 20(12)：1913-1927.
2. Medioni J， Huchon C， Le Frere-Belda MA， et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer：improved prognosis in triple-negative tumors[J]. Drugs RD， 2011， 11(2)：147-157.
3. Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
4. Hanley K， Wang J， Bourne P， et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol， 2008， 39(3)：386-392.
5. Pristauz G， Petru E， Stacher E， et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology， 2010， 57(6)：877-884.
6. Tang D， Xu S， Zhang Q， et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol， 2012， 29(2)：526-533.
7. Doane AS， Danso M， Lal P， et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene， 2006， 25(28)：3994-4008.
8. Agoff SN， Swanson PE， Linden H， et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical， clinical， and prognostic associations[J]. Am J Clin Pathol， 2003， 120(5)：725-731.
9. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer， 2000， 83(3)：311-318.
10. Baquero MT， Hanna JA， Neumeister V， et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer， 2012， 118(19)：4660-4669.
11. Rakha EA， Aleskandarany M， El-Sayed ME， et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer， 2009， 45(10)：.
12. Cao AY， He M， Liu ZB， et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma：a population-based study from China[J]. Ann Surg Oncol， 2012， 19(9)：3019-3027.
13. Chen WY， Chen CS， Chen HC， et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int， 2004， 54(10)：781-786.
14. Shah C， Wilkinson JB， Shaitelman S， et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys， 2011， 81(4)：.
15. Fernández B， Paish EC， Green AR， et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol， 2011， 64(11)：995-1000.
16. Lerma E， Peiro G， Ramón T， et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors，progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol， 2007， 20(11)：1200-1207.
17. Millikan RC， Newman B， Tse CK， et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat， 2008， 109(1)：123-139.
18. Dent R， Trudeau M， Pritchard KI， et al. Triple-negative breast cancer：clinical features and patterns of recurrence[J]. Clin Cancer Res， 2007， 13(15 Pt 1)：4429-4434.
19. Cimino-Mathews A， Hicks JL， Illei PB， et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol， 2012， 43(7)：1003-1011.
20. Park S， Koo J， Park HS， et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology ：official journal of the European Society for Medical Oncology / ESMO， 2010， 21(3)：488-492.
21. Niemeier LA， Dabbs DJ， Beriwal S， et al. Androgen receptor in breast cancer：expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol， 2010， 23(2)：205-212.
22. Qi JP， Yang YL， Zhu H， et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl)， 2012， 6：1-8.
23. Gonzalez-Angulo AM， Stemke-Hale K， Palla SL， et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res， 2009， 15(7)：2472-2478.
24. Loibl S， Müller BM， von Minckwitz G， et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat， 2011， 130(2)：477-487.
25. Holmfeldt P， Sellin ME， Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci， 2009， 66(20)：3263-3276.
26. Singer S， Ehemann V， Brauckhoff A， et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology， 2007， 46(3)：759-768.
27. Alli E， Bash-Babula J， Yang JM， et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res， 2002， 62(23)：6864-6869.
28. Alli E， Yang JM， Ford JM， et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol， 2007， 71(5)：1233-1240.
29. Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer， 2010， 10(3)：194-204.
30. -551.
31. -1787.
  1. 1. Gluz O， Liedtke C， Gottschalk N， et al. Triple-negative breast cancer-current status and future directions[J]. Ann Oncol， 2009， 20(12)：1913-1927.
  2. 2. Medioni J， Huchon C， Le Frere-Belda MA， et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epiru-bicin for operable breast cancer：improved prognosis in triple-negative tumors[J]. Drugs RD， 2011， 11(2)：147-157.
  3. 3. Liedtke C， Mazouni C， Hess KR， et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol， 2008， 26(8)：1275-1281.
  4. 4. Hanley K， Wang J， Bourne P， et al. Lack of expression of andr-ogen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast[J]. Hum Pathol， 2008， 39(3)：386-392.
  5. 5. Pristauz G， Petru E， Stacher E， et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 muta-tions[J]. Histopathology， 2010， 57(6)：877-884.
  6. 6. Tang D， Xu S， Zhang Q， et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J]. Med Oncol， 2012， 29(2)：526-533.
  7. 7. Doane AS， Danso M， Lal P， et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen[J]. Oncogene， 2006， 25(28)：3994-4008.
  8. 8. Agoff SN， Swanson PE， Linden H， et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical， clinical， and prognostic associations[J]. Am J Clin Pathol， 2003， 120(5)：725-731.
  9. 9. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors[J]. Br J Cancer， 2000， 83(3)：311-318.
  10. 10. Baquero MT， Hanna JA， Neumeister V， et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer， 2012， 118(19)：4660-4669.
  11. 11. Rakha EA， Aleskandarany M， El-Sayed ME， et al. The prognosticsignificance of inflammation and medullary histological type ininvasive carcinoma of the breast[J]. Eur J Cancer， 2009， 45(10)：.
  12. 12. Cao AY， He M， Liu ZB， et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma：a population-based study from China[J]. Ann Surg Oncol， 2012， 19(9)：3019-3027.
  13. 13. Chen WY， Chen CS， Chen HC， et al. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma[J]. Pathol Int， 2004， 54(10)：781-786.
  14. 14. Shah C， Wilkinson JB， Shaitelman S， et al. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma[J]. Int J Radiat Oncol Biol Phys， 2011， 81(4)：.
  15. 15. Fernández B， Paish EC， Green AR， et al. Lymph-node metastasesin invasive lobular carcinoma are different from those in ductal carcinoma of the breast[J]. J Clin Pathol， 2011， 64(11)：995-1000.
  16. 16. Lerma E， Peiro G， Ramón T， et al. Immunohistochemical hetero-geneity of breast carcinomas negative for estrogen receptors，progesterone receptors and Her2/neu (basal-like breast carcinomas)[J]. Mod Pathol， 2007， 20(11)：1200-1207.
  17. 17. Millikan RC， Newman B， Tse CK， et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat， 2008， 109(1)：123-139.
  18. 18. Dent R， Trudeau M， Pritchard KI， et al. Triple-negative breast cancer：clinical features and patterns of recurrence[J]. Clin Cancer Res， 2007， 13(15 Pt 1)：4429-4434.
  19. 19. Cimino-Mathews A， Hicks JL， Illei PB， et al. Androgen receptorexpression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy[J]. Hum Pathol， 2012， 43(7)：1003-1011.
  20. 20. Park S， Koo J， Park HS， et al. Expression of androgen receptorsin primary breast cancer[J]. Annals of oncology ：official journal of the European Society for Medical Oncology / ESMO， 2010， 21(3)：488-492.
  21. 21. Niemeier LA， Dabbs DJ， Beriwal S， et al. Androgen receptor in breast cancer：expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation[J]. Mod Pathol， 2010， 23(2)：205-212.
  22. 22. Qi JP， Yang YL， Zhu H， et al. Expression of the androgen receptorand its correlation with molecular subtypes in 980 Chinese breast cancer patients[J]. Breast Cancer (Auckl)， 2012， 6：1-8.
  23. 23. Gonzalez-Angulo AM， Stemke-Hale K， Palla SL， et al. Androgenreceptor levels and association with PIK3CA mutations and prognosis in breast cancer[J]. Clin Cancer Res， 2009， 15(7)：2472-2478.
  24. 24. Loibl S， Müller BM， von Minckwitz G， et al. Androgen receptorexpression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat， 2011， 130(2)：477-487.
  25. 25. Holmfeldt P， Sellin ME， Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization[J]. Life Sci， 2009， 66(20)：3263-3276.
  26. 26. Singer S， Ehemann V， Brauckhoff A， et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis[J]. Hepatology， 2007， 46(3)：759-768.
  27. 27. Alli E， Bash-Babula J， Yang JM， et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J]. Cancer Res， 2002， 62(23)：6864-6869.
  28. 28. Alli E， Yang JM， Ford JM， et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells[J]. Mol Pharmacol， 2007， 71(5)：1233-1240.
  29. 29. Kavallaris M. Microtubules and resistance to tubulin-binding agents[J]. Nat Rev Cancer， 2010， 10(3)：194-204.
  30. 30. -551.
  31. 31. -1787.